United Therapeutics
UTHR
566 hedge funds and large institutions have $14.6B invested in United Therapeutics in 2024 Q2 according to their latest regulatory filings, with 104 funds opening new positions, 202 increasing their positions, 192 reducing their positions, and 55 closing their positions.
89% more first-time investments, than exits
New positions opened: 104 | Existing positions closed: 55
64% more funds holding in top 10
Funds holding in top 10: 11 → 18 (+7)
41% more capital invested
Capital invested by funds: $10.4B → $14.6B (+$4.22B)
8% more funds holding
Funds holding: 525 → 566 (+41)
7.33% more ownership
Funds ownership: 96.25% → 103.58% (+7.3%)
5% more repeat investments, than reductions
Existing positions increased: 202 | Existing positions reduced: 192
1% more call options, than puts
Call options by funds: $281M | Put options by funds: $279M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$393M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$116M |
| 3 |
State Street
Boston,
Massachusetts
|
+$95M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$90.2M |
| 5 |
Amundi
Paris,
France
|
+$81.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$190M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$113M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$69.9M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$67.2M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$59.6M |
UTHR Hedge Fund Activity: Q2 2024 in Review
566 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2024, worth a combined $14.6B — up 41% from $10.4B a quarter earlier.
Buyers outnumbered sellers: 104 funds opened new UTHR positions and 55 closed out — a net gain of 49 holders — while 202 added to existing stakes and 192 trimmed.
The largest buyer was Citigroup, adding an estimated $393M. The largest seller was Citadel Advisors, exiting entirely with an estimated $190M sold.
- 566 institutional investors held United Therapeutics (UTHR) as of Q2 2024, up from 525 in Q1 2024.
- Funds reported $14.6B of United Therapeutics stock for Q2 2024, up 41% quarter-over-quarter.
- 104 funds opened new United Therapeutics positions in Q2 2024 and 55 closed out, a net change of +49 holders.
- The largest United Therapeutics buyer in Q2 2024 was Citigroup, an estimated $393M added.
- The largest United Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $190M sold.
Based on aggregated 13F filings for Q2 2024.